Zogenix adds $60 million equity to take lead to NDA and fund operations until 2013
This article was originally published in Scrip
Executive Summary
Zogenix, which is moving forward with an expected NDA filing in early 2012 with its lead chronic pain candidate known as Zohydro, has raised $60 million through the sale of 30 million shares at $2, a discount to the $2.17 share price when the offer was announced on 15 September.